drugset / Trial / NCT07527520

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial

NCT07527520

Phase 2 Not yet recruiting 165 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with high-risk locally advanced colorectal cancer.

Timeline

Start
2026-06
Primary completion
2028-07
Completion
2031-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Serplulimab Monoclonal antibody 300 mg Intravenous

Indications